Advertisement
Ear/Nose/Throat
Subscribe to Ear/Nose/Throat
View Sample

FREE Email Newsletter

Simpler Genome Sequencing

May 13, 2011 2:35 pm | by Massachusetts Institute of Technology | News | Comments

A startup hopes to make the technology cheap enough that it's feasible for a typical hospital lab.

FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors

May 6, 2011 6:42 am | by Bio-Medicine.Org | News | Comments

MANHATTAN BEACH, Calif., May 6, 2011 /- Yesterday, the U.S. Food and Drug Administration (FDA) approved the Novartis drug Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors.  Neuroendocrine tumors make up less than five percent of all...

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

May 5, 2011 5:35 pm | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., May 5, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients...

Advertisement

New CE Marked Test Simultaneously Detects Up To 95% of Gastrointestinal Infections in Under Five Hours

May 4, 2011 10:40 pm | by Bio-Medicine.Org | News | Comments

AUSTIN, Texas and MILAN, May 5, 2011 /- Luminex Corporation (NASDAQ: LMNX ) announced today that it has received CE marking for its new xTAG Gastrointestinal Pathogen Panel (GPP).This innovative assay is the first test of its kind to help identify up to 95 percent of the disease causing...

Immunetics lands $2.4M NIH grant for parasite detection

May 3, 2011 7:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Infectious disease testing company Immunetics Inc. has won a three-year, $2.4 million Phase 2 SBIR grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

IRIDEX Announces First Quarter 2011 Conference Call and Release Date

April 28, 2011 8:34 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., April 28, 2011 /- IRIDEX Corporation (NASDAQ: IRIX ) today announced that it will release its first quarter 2011 financial results after the market closes on Thursday, May 5, 2011.  In conjunction with the release, the Company will host a conference call with...

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 13th International Myeloma Workshop

April 28, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

SOUTH SAN FRANCISCO, Calif., April 28, 2011 /- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 13th International Myeloma Workshop (IMW), May 3-6, 2011, in...

Sacramento Police Upgrades Search and Rescue Technology with EmSeeQ® Wearable Locator System to Improve Safety for At-Risk Adults and Children

April 27, 2011 6:36 am | by Bio-Medicine.Org | News | Comments

FRISCO, Texas, April 27, 2011 /- The City of Sacramento Police Department (Calif.) is proud to announce today the availability of the EmFinder's EmSeeQ® wearable locator system that uses cellular technology to quickly locate individuals who are prone to wandering due to cognitive...

Advertisement

Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy

April 26, 2011 5:36 pm | by Bio-Medicine.Org | News | Comments

BOCA RATON, Fla., April 26, 2011 /- The Premier healthcare alliance, a network of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites working together to achieve high quality, cost-effective care, has awarded Sensus Healthcare, Inc. , the leading provider of FDA-approved...

Sanare and BrightSky Announce National Strategic Partnership with American Diabetes Association

April 21, 2011 6:35 am | by Bio-Medicine.Org | News | Comments

RENO, Nev., April 21, 2011 /- Sanare, LLC, a leading provider of care management solutions for people with diabetes, and its new consumer brand, BrightSky, have become National Strategic Partners of the American Diabetes Association.® (Logo:...

Daughter of Journalist Robert MacNeil States that Son Regressed Into Autism After Vaccines

April 19, 2011 3:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA, April 19, 2011 /PRNewswire-USNewswire/ -- Alison MacNeil issued the following statements today regarding vaccines. MacNeil's family Autism story is running on PBS this week: "When I vaccinated my son Nick, I did not know vaccine manufacturers are not required to test the safety...

FDA Approves New Medical Device for Form of Brain Cancer

April 15, 2011 11:35 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., April 15, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme (GBM) that recurs or progresses after receiving chemotherapy and radiation therapy....

Merz Pharmaceuticals Joins Patient Advocates to Raise Awareness of Cervical Dystonia and Blepharospasm

April 14, 2011 6:37 am | by Bio-Medicine.Org | News | Comments

GREENSBORO, N.C., April 14, 2011 /- Merz Pharmaceuticals, LLC, maker of XEOMIN® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign. With the help of patient advocates, "Make Your Mark" celebrates...

Advertisement

New Data Show Low Incidence of Augmentation of Restless Legs Syndrome With 5-Year Neupro® (rotigotine) Treatment

April 14, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

BRUSSELS, April 14, 2011 /- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation. Over the five year period, clinically...

Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study

April 12, 2011 8:37 am | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., April 12, 2011 /- Max Neeman meets enrollment and timeline of 15,000 for a large, Phase IV metabolic disorder trial across 1200 sites throughout India. As a leading Indian CRO, the company has completed multiple Phase IV studies for global sponsors with...

FDA Clears Single-Use Antibacterial Surgical Respirator

April 8, 2011 12:35 pm | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., April 8, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration cleared the SpectraShield 9500 N95 surgical respirator, a device that kills 99.99 percent of three different kinds of bacteria when exposed to its outer surface. (Logo:  ...

SRI International Drug Candidate Shows Promise for Treating and Preventing Prostate Cancer

March 30, 2011 9:37 am | by Bio-Medicine.Org | News | Comments

MENLO PARK, Calif., March 30, 2011 /- The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate...

Allergy Relief Moms Can Rely On

March 30, 2011 7:35 am | by Bio-Medicine.Org | News | Comments

IRVINGTON, N.Y., March 30, 2011 /- Itchy, runny nose, sneezing, watery eyes and itchy throat – we all know the symptoms that can make our children miserable from allergies. And just in the nick of time as we approach the peak allergy season, PediaCare® , a trusted brand of...

<i>Patent Watch: </i>Gene patents flow into New England

March 29, 2011 8:34 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Suffolk Law School professor Kirk Teska: Gene patents are back in the news, so let's take a look at several gene related patents and published patent applications naming New England inventors of the last year.

FDA Approves New Treatment for a Type of Late-Stage Skin Cancer

March 25, 2011 9:36 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO...

Gateway to Hope: Missouri Nonprofit Leads the Fight against Breast Cancer by Providing Donated Medical and Surgical Care at No Cost to Patients

March 24, 2011 4:34 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, March 24, 2011 /- Frustrated at seeing patients die because of lack of insurance or financial means, Dr. David A. Caplin and Dr. Marlys E. Schuh founded Gateway to Hope in St. Louis, Missouri in 2005. Based on the belief that every person diagnosed with breast cancer should be...

Student's love for family apparent in his 2 for OneShot system

March 22, 2011 10:35 am | by Arizona State University | News | Comments

From homelessness to greatness, ASU student Tyler Eltringham has seen the ups and downs of life. read more

Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution

March 21, 2011 4:35 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., March 21, 2011 /- Life Technologies Corporation (Nasdaq: LIFE ) today announced that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human...

Research: Prostate cancer patients opt for more expensive treatment

March 17, 2011 11:34 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Men diagnosed with prostate cancer have been rapidly adopting new, more expensive treatment options, even without proof of their cost-effectiveness, according to research by the Dana-Farber/Brigham and Women's Hospital Cancer Center.

Research: Prostrate cancer patients opt for more expensive treatment

March 17, 2011 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Men diagnosed with prostate cancer have been rapidly adopting new, more expensive treatment options, even without proof of their cost-effectiveness, according to research by the Dana-Farber/Brigham and Women's Hospital Cancer Center.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading